Ulcerative colitis is a category of inflammatory bowel disease that results in inflammation and sores in the digestive tract. Ulcerative colitis affects the inner lining of the large intestine (colon) and rectum. Usually, symptoms can be seen gradually depending upon the severity of inflammation. Mild symptoms can be cured by drug therapy but surgical treatment is needed in case of severity. Ulcerative colitis may lead to colon cancer if persists for over 8 years or longer. Increasing healthcare preventative measures also progressively becoming more and more sensitive to seek the advantages of the therapy. In preventative healthcare, drugs and novel therapies also reduce the chance of getting colon cancer. Possible complications associated with ulcerative colitis include perforated colon, a rapidly swelling colon, severe bleeding, and osteoporosis, increased risk of blood clots in veins and arteries, and severe dehydration. The exact cause of ulcerative colitis is not known, but the possible reasons can be genetic factors, environmental changes, or a malfunctioning immune system. The ulcerative colitis can be prevented by simple healthy habits such as eating small meals throughout the day, staying well hydrated throughout the day, avoiding fatty foods, and limiting the intake of high-fiber food.
China Ulcerative Colitis Market - Impact of the Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdown in various countries across the globe have impacted the financial status of businesses across all sectors including private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Several countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation and distribution of healthcare products. The management of inflammatory bowel disease (IBD) has been severely impacted by the COVID-19 pandemic, with strictly limited hospitalizations and delaying diagnostic procedures.
Thus, impact of the Coronavirus (COVID-19) pandemic is expected to limit the growth of the China ulcerative colitis market during the forecast period. For instance, according to an article published in April 2020, in the Lancet, Coronavirus (COVID-19) pandemic is altering the treatment of various chronic diseases, such as ulcerative colitis, and inflammatory bowel disease patients (IBD). Moreover, routine endoscopy, in particular, was temporarily suspended in the hospitals, but the government has given permission for emergency endoscopy in several countries where the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) has spread. In the midst of the pandemic, there are currently no specific endoscopic recommendations for patients with IBD based on direct evidence. Patients with IBD were advised to follow the World Health Organization (WHO)'s general public health measures, particularly those on systemic corticosteroids, thiopurine, and biologics, as they are considered to be moderate-to-high risk patients who are susceptible to COVID-19 and its complications.
The China ulcerative colitis market is estimated to be valued at US$ 246.3 Mn in 2022 and is expected to exhibit a CAGR of 3.3% over the forecast period (2022-2030)
Figure 1: China Ulcerative Colitis Market Share, (%), Analysis, By Drug Therapy, 2022
Market players are indulged in conducting research and development activities, in order to develop innovative treatment for ulcerative colitis. This is expected to drive growth of the China ulcerative colitis market over the forecast period.
Market players are conducting research and development activities, for the development of new treatment for ulcerative colitis. This is expected to drive the growth of the China ulcerative colitis market, over the forecast period. For instance, in 2021, Connect Biopharma, a China-based biopharmaceutical company, concluded subject enrolment in the phase II clinical trial of its orally available therapy, CBP-307, in adults with moderate-to-severe ulcerative colitis (UC). CBP-307 is a small molecule modulator of sphingosine-1-phosphate 1 receptor (S1P1).
Moreover, in 2021, Reistone Biopharma Co. Ltd., a clinical-stage biopharmaceutical company headquartered in China, announced positive results for the phase II clinical trial which was conducted in order to evaluate the safety and efficacy of its drug candidate, SHR0302, an investigational selective Janus kinase type 1 (JAK1) inhibitor, for the treatment of moderate-to-severe ulcerative colitis. Currently, the trials are carried out in China, the U.S. and other countries. The company was planning to initiate phase III clinical trial in 2021.
|Base Year:||2021||Market Size in 2022:||US$ 190.2 Mn|
|Historical Data for:||2018 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||3.3%||2030 Value Projection:||US$ 246.3 Mn|
AbbVie Inc, Celltrion Healthcare, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche AG, Arena Pharmaceuticals, Takeda Pharmaceuticals Company Ltd., GlaxoSmithKline Plc., Eli Lilly and Company, AstraZeneca, Pfizer Inc., Amgen Inc., BRISTOL-MYERS SQUIBB, ZERIA Pharmaceutical Co., Ltd., InDex Pharmaceuticals Holding AB, Mitsubishi Tanabe Pharma Corporation, Salix Pharmaceuticals, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., EA Pharma Co., Ltd., Theravance Biopharma, and HUTCHMED
|Restraints & Challenges:||
Market players are focusing on signing agreements with the other companies, this is expected to drive the growth of the China ulcerative colitis market, over the forecast period
Increasing number of agreements from the companies is expected to drive the growth of the China ulcerative colitis market, over the forecast period. For instance, in March 2021, InDex Pharmaceuticals Holding AB, a pharmaceutical company, announced that the company had entered into an agreement for services with a clinical research organization (CRO) Parexel Biotech for the phase III study CONCLUDE. The study evaluates the efficacy and safety of the drug candidate cobitolimod for the treatment of moderate to severe left-sided ulcerative colitis.
In April 2019, Salix Pharmaceuticals, a pharmaceutical company announced that it had entered into an exclusive licensing agreement with Mitsubishi Tanabe Pharma Corporation, a Japanese pharmaceuticals company, to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate (S1P) receptor that plays a role in autoimmune diseases such as inflammatory bowel disease (IBD) and ulcerative colitis.
China Ulcerative Colitis Market – Restraints
Most of the clinical trials that were being carried out for finding the treatment of ulcerative colitis are terminated and this is expected to hamper the growth of the China ulcerative colitis market, over the forecast period. For instance, in 2021, Takeda Pharmaceutical Company Limited, a pharmaceutical company, terminated its clinical trial for Ontamalimab (Phase III) which was tested for the treatment of ulcerative colitis. The trial was terminated due to the decision of the sponsor to discontinue the SHP647 (Ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD).
In 2021, Pfizer Inc. terminated its clinical trial for PF-06687234 (Phase II), which was tested for the treatment of ulcerative colitis. The trial was terminated as the sponsor changed its R&D strategy and priority.
Figure 2: China Ulcerative Colitis Market Value (US$ Mn) & Y-o-Y Growth (%), 2022 – 2030
China Ulcerative Colitis Market – Competitive Landscape
Major players operating in the China ulcerative colitis market include AbbVie Inc, Celltrion Healthcare, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche AG, Arena Pharmaceuticals, Takeda Pharmaceuticals Company Ltd., GlaxoSmithKline Plc., Eli Lilly and Company, AstraZeneca, Pfizer Inc., Amgen Inc., BRISTOL-MYERS SQUIBB, ZERIA Pharmaceutical Co., Ltd., InDex Pharmaceuticals Holding AB, Mitsubishi Tanabe Pharma Corporation, Salix Pharmaceuticals, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., EA Pharma Co., Ltd., Theravance Biopharma, and HUTCHMED
Ulcerative colitis is the most common type of inflammatory bowel disease that affects the colon (lining of the large intestine) and rectum. The inflammation produces tiny sores called ulcers. This disease can affect people of any age. The major symptoms of this disease include diarrhea, belly pain/cramps, bleeding from the rectum, also other indications include sudden and unexplained weight loss, loss of appetite, joint pain, eye disease, thickening of the intestinal wall, blood infection (sepsis), kidney stones, and liver disease. The diagnosis of this disease can be carried out by physical examination using tests such as colonoscopy, endoscopy, biopsy, CT scan, and blood test. If ulcerative colitis persists for over eight years or longer, it may lead to colon cancer.
The people having mild symptoms of this disease can be cured by over-the-counter drugs such as Imodium therapy. However, transcription medicine such as steroid medicines and amino salicylates are widely used to treat the condition. In severe cases, the patient may need to undergo surgery to remove the colon, which also helps to prevent colon cancer. The exact cause for ulcerative colitis is unknown, though possible reasons are may be genetic factors, environmental changes, or weakened immune system.
Market players are engaged in receiving approvals from the regulatory authorities, this is expected to drive the growth of the China ulcerative colitis market, over the forecast period. For instance, in 2019, in April, AbbVie announced that the U.S. Food and Drug Administration approved SKYRIZI (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. The drug Risankizumab is the product of a partnership between Boehringer Ingelheim, a research driven pharmaceutical company and AbbVie.
Moreover, in 2019, Janssen Biotech, Inc., a subsidiary of Johnson & Johnson received the U.S. Food and Drug Administration (FDA) approval for STELARA (ustekinumab) for the treatment of adult patients with moderate-to-severe active ulcerative colitis.
Key players are focusing on conducting research and development activities for finding the treatment for the ulcerative colitis and this is expected to increase the growth of the China ulcerative colitis market, over the forecast period. For instance, In August, InDex Pharmaceuticals Holding AB announced positive top line results from the dose optimization study CONDUCT (Cobitolimod as Novel DNA-based Ulcerative Colitis Treatment), which evaluated cobitolimod for the treatment of moderate to severe ulcerative colitis
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.